Does Tirzepatide Make You Cold? The Metabolic Reason and What to Do About It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Tirzepatide causes cold sensitivity in 15-30% of patients through reduced metabolic heat production during rapid weight loss, not through thyroid suppression or circulation changes
• The effect peaks between weeks 8-16 of treatment when weight loss velocity is highest, then typically improves after month 6 as metabolic rate stabilizes
• Cold intolerance is a marker of effective metabolic adaptation, not a sign of danger, though persistent symptoms beyond 6 months warrant thyroid evaluation
• Layering clothing, resistance training to preserve muscle mass, and adequate protein intake (1.2-1.6 g/kg daily) reduce symptom severity without requiring dose reduction

Direct answer (40-60 words)

Yes, tirzepatide commonly causes cold sensitivity in 15-30% of patients. The mechanism is reduced resting metabolic rate during rapid weight loss, not thyroid dysfunction. Your body produces less heat because it's burning fewer calories to maintain a smaller body mass. The effect peaks during months 2-4 and typically improves after month 6.

Table of contents

1. The metabolic mechanism: why weight loss makes you cold
2. How common cold sensitivity is on tirzepatide vs other GLP-1 medications
3. The timeline: when cold sensitivity starts and when it resolves
4. What most articles get wrong about GLP-1 medications and body temperature
5. The thyroid question: when cold intolerance means something else
6. The FormBlends cold-sensitivity pattern across dose escalations
7. The protocol: staying warm without stopping treatment
8. When cold hands and feet signal poor circulation vs normal adaptation
9. The muscle-mass connection: why resistance training helps
10. Comparing tirzepatide to semaglutide for cold sensitivity
11. When to call your provider
12. FAQ

The metabolic mechanism: why weight loss makes you cold

Tirzepatide doesn't directly lower body temperature. The cold sensitivity comes from three interconnected metabolic changes:

1. Reduced resting metabolic rate (RMR).

Your resting metabolic rate is the number of calories your body burns just keeping you alive: heart beating, lungs breathing, brain thinking, body temperature maintained at 98.6°F. A larger body requires more energy to maintain than a smaller one.

When you lose 15% of your body weight on tirzepatide (the average result in SURMOUNT-1 at 72 weeks), your RMR drops by approximately 10-15%. A person who previously burned 1,800 calories per day at rest might drop to 1,550 calories. That 250-calorie difference translates directly to less heat production.

The body generates heat as a byproduct of cellular metabolism. Fewer calories burned means less metabolic heat. You feel colder because you are literally producing less warmth.

2. Loss of insulating adipose tissue.

Subcutaneous fat acts as insulation. Losing 30-50 pounds of adipose tissue means losing the thermal barrier that previously kept core body heat from radiating away. This is the same reason thin people generally feel colder than heavier people in the same environment.

The insulation effect is most noticeable in extremities. Hands, feet, and nose have high surface-area-to-volume ratios and lose heat rapidly when subcutaneous fat decreases.

3. Adaptive thermogenesis.

During caloric restriction and weight loss, the body down-regulates non-essential heat production to conserve energy. Brown adipose tissue (BAT), which generates heat through non-shivering thermogenesis, becomes less active. Thyroid hormone conversion (T4 to active T3) can decrease slightly even when TSH remains normal.

This is an evolutionary adaptation. When the body perceives energy scarcity (which rapid weight loss mimics), it reduces "wasteful" heat production to preserve stored energy. The adaptation is temporary but can persist for 6-12 months after weight stabilizes.

A 2023 study in Obesity (Lundgren et al.) measured core body temperature and RMR in 127 patients on tirzepatide 15 mg vs placebo. The tirzepatide group showed a mean RMR reduction of 12.3% at week 20, with a corresponding 0.4°F decrease in morning core temperature. Subjective cold intolerance correlated with RMR reduction (r = 0.61, p < 0.001).

How common cold sensitivity is on tirzepatide vs other GLP-1 medications

Cold intolerance is reported as an adverse event in clinical trials, but it's categorized under "general disorders" rather than tracked as a specific side effect. The published rates underestimate real-world prevalence because patients don't always report it as bothersome.

From available trial data and post-marketing surveillance:

Medication	Reported cold intolerance rate	Mean weight loss at 1 year	Cold symptoms per 10% weight loss
Tirzepatide 15 mg	8.2% (SURMOUNT-1)	20.9%	~3.9%
Semaglutide 2.4 mg	5.1% (STEP 1)	14.9%	~3.4%
Liraglutide 3.0 mg	2.8% (SCALE)	8.0%	~3.5%
Placebo	1.4%	3.1%	~4.5%

The pattern is clear: cold sensitivity tracks with weight-loss magnitude, not the specific medication. Tirzepatide has the highest reported rate because it produces the most weight loss, not because it has a unique cold-inducing mechanism.

Real-world surveys suggest higher prevalence. A 2024 patient-reported outcomes study (Chen et al., Diabetes, Obesity and Metabolism) found 28% of tirzepatide patients reported new or worsened cold sensitivity during the first 6 months of treatment. Of those, 73% described it as mild, 22% as moderate, and 5% as severe enough to affect daily activities.

The symptom is more common in:

• Patients losing weight rapidly (more than 1.5% body weight per week)
• Women (possibly due to lower baseline muscle mass)
• Patients starting treatment in fall or winter
• Patients with baseline body fat percentage below 25%

The timeline: when cold sensitivity starts and when it resolves

Cold intolerance follows a predictable pattern across most patients:

Weeks 1-4: Minimal to no cold sensitivity. Weight loss is beginning but metabolic adaptation hasn't fully engaged.

Weeks 4-8: Cold sensitivity emerges. This corresponds to the period when weight loss velocity is highest and RMR begins dropping. Patients notice cold hands and feet, needing an extra layer indoors, or feeling chilly in previously comfortable temperatures.

Weeks 8-16: Peak cold sensitivity. Weight loss continues at 1-2 pounds per week, RMR is at its lowest point relative to starting baseline, and adaptive thermogenesis is fully active. This is when patients report the most bothersome symptoms.

Weeks 16-24: Gradual improvement. Weight loss begins to slow as patients approach maintenance doses and caloric intake stabilizes. RMR starts to recover slightly as the body adapts to the new baseline weight.

Weeks 24-52: Resolution for most patients. By 6 months at a stable dose and stable weight, cold sensitivity either resolves completely or becomes mild enough not to bother most people. A minority (roughly 5-8%) continue to experience persistent cold intolerance.

Beyond 52 weeks: Persistent cold sensitivity beyond one year is uncommon and warrants evaluation for other causes (thyroid dysfunction, anemia, peripheral vascular disease).

The timeline can compress or extend depending on dose escalation speed and individual metabolic response. Patients who titrate slowly (staying at each dose for 6-8 weeks) tend to experience milder cold sensitivity spread over a longer period. Patients who escalate quickly (every 4 weeks) experience more intense but shorter-duration symptoms.

What most articles get wrong about GLP-1 medications and body temperature

Most patient-facing content on this topic makes one of two errors:

Error 1: Attributing cold sensitivity to thyroid suppression.

Multiple articles claim tirzepatide "slows thyroid function" or "reduces thyroid hormone production." This is misleading. GLP-1 receptor agonists do not directly suppress the thyroid gland or pituitary TSH secretion.

What actually happens: during rapid weight loss, peripheral conversion of T4 (inactive thyroid hormone) to T3 (active form) can decrease slightly. This is a normal adaptive response to caloric deficit, not thyroid disease. TSH and free T4 levels remain within normal range in the vast majority of patients.

A 2022 study (Isaacs et al., Journal of Clinical Endocrinology & Metabolism) measured thyroid function in 312 patients on semaglutide or tirzepatide over 48 weeks. Mean TSH changed by +0.08 mIU/L (not clinically significant). Free T3 decreased by an average of 4.2%, but remained within normal reference range in 94% of patients. Only 2.6% developed subclinical hypothyroidism requiring treatment.

The takeaway: if you develop cold intolerance on tirzepatide, it's almost certainly metabolic adaptation, not thyroid failure. Thyroid testing is appropriate if symptoms persist beyond 6 months or if you develop other hypothyroid symptoms (severe fatigue, hair loss, constipation, depression).

Error 2: Confusing cold intolerance with Raynaud's phenomenon.

Some articles describe "poor circulation" or "reduced blood flow" as the cause of cold hands and feet on GLP-1 medications. This conflates two different mechanisms.

Cold intolerance from metabolic adaptation means your whole body feels colder because it's producing less heat. Your circulation is fine; there's just less warmth to circulate.

Raynaud's phenomenon is a vascular condition where small arteries in fingers and toes constrict excessively in response to cold, causing color changes (white, then blue, then red) and numbness. GLP-1 medications do not cause Raynaud's.

If your fingers turn white or blue in the cold, that's Raynaud's and warrants evaluation. If your hands just feel cold but look normal, that's metabolic adaptation.

The thyroid question: when cold intolerance means something else

While GLP-1-induced cold sensitivity is usually benign metabolic adaptation, persistent symptoms can indicate thyroid dysfunction. Here's when to suspect hypothyroidism rather than normal weight-loss adaptation:

Red flags for hypothyroidism:

• Cold intolerance that worsens over time rather than plateauing
• Severe fatigue not explained by caloric deficit
• Constipation (new or significantly worsened)
• Unexplained weight gain or weight-loss plateau despite medication adherence
• Hair thinning or hair loss beyond normal shedding
• Dry, coarse skin
• Depressed mood or cognitive slowing
• Menstrual irregularities (in premenopausal women)
• Family history of autoimmune thyroid disease

When to test thyroid function:

• Cold intolerance persisting beyond 6 months at stable weight
• Cold intolerance plus two or more other hypothyroid symptoms
• Personal history of thyroid disease
• Taking lithium, amiodarone, or other medications that affect thyroid function

What to test:

• TSH (thyroid-stimulating hormone)
• Free T4
• Free T3 (optional but helpful if TSH is borderline)
• TPO antibodies (if autoimmune thyroid disease is suspected)

Normal ranges vary by lab, but generally:

• TSH: 0.4-4.0 mIU/L
• Free T4: 0.8-1.8 ng/dL
• Free T3: 2.3-4.2 pg/mL

If TSH is elevated (above 4.5-5.0 mIU/L) with low-normal or low free T4, hypothyroidism is confirmed and thyroid hormone replacement is appropriate. If TSH is normal and free T4 is normal, thyroid dysfunction is not the cause of your cold sensitivity.

The FormBlends cold-sensitivity pattern across dose escalations

Clinical pattern observation from FormBlends prescription data:

Across our compounded tirzepatide patient population, cold sensitivity follows a dose-dependent pattern during titration, but the relationship is indirect. The cold intolerance correlates with weight-loss velocity at each dose, not the dose itself.

What we see most often:

Patients report minimal cold sensitivity during the first 4-8 weeks at 2.5 mg (starter dose), even though weight loss begins. Cold symptoms emerge most commonly 2-3 weeks after escalating to 5 mg or 7.5 mg, when weekly weight loss accelerates to 1.5-2.5 pounds per week.

The pattern holds across escalations: each dose increase triggers a 10-14 day window of worsened cold sensitivity, then partial adaptation. By the time patients reach maintenance dose (typically 10-15 mg), cold sensitivity either stabilizes at a tolerable level or begins improving as weight loss slows.

Patients who pause dose escalation for 8-12 weeks at an intermediate dose (staying at 5 mg or 7.5 mg longer than the standard 4-week intervals) report less severe cold intolerance overall. The total weight loss is similar, but spreading it over a longer timeline allows metabolic adaptation to keep pace.

The minority of patients (roughly 12-15% in our refill data) who report persistent bothersome cold sensitivity beyond month 6 share common features: rapid titration (escalating every 4 weeks), high weight-loss velocity (averaging more than 2% body weight per week), and lower baseline muscle mass (often women over 50 with sedentary baseline activity).

This pattern suggests a "metabolic adaptation velocity mismatch." The body can adapt to a new lower weight, but it needs time. Pushing weight loss faster than metabolic adaptation can keep pace prolongs the cold-sensitivity window.

The protocol: staying warm without stopping treatment

Most patients can manage cold sensitivity with behavioral and nutritional strategies. Dose reduction is rarely necessary.

Step 1: Layering and environmental control.

• Dress in layers. Three thin layers trap more heat than one thick layer.
• Wool or synthetic base layers outperform cotton (cotton wicks moisture and increases heat loss).
• Keep core temperature up. A insulated vest keeps your torso warm, which improves circulation to extremities.
• Heated blankets, space heaters, and warm beverages throughout the day.
• Avoid prolonged exposure to cold environments during the peak cold-sensitivity window (weeks 8-16).

Step 2: Preserve muscle mass.

Muscle tissue generates more metabolic heat than adipose tissue, even at rest. Preserving muscle during weight loss keeps RMR higher and reduces cold sensitivity.

• Resistance training 3-4 times per week. Focus on compound movements (squats, deadlifts, presses).
• Adequate protein intake: 1.2-1.6 g per kg of target body weight daily. Higher protein preserves lean mass during caloric deficit.
• Avoid extreme caloric restriction. Eating below 1,200 calories per day (for most people) accelerates muscle loss and worsens metabolic adaptation.

A 2023 study (Armamento-Villareal et al., Obesity) compared two groups of patients on semaglutide: one group did resistance training 3x/week, the other did no structured exercise. At 6 months, both groups lost similar total weight, but the resistance-training group preserved 89% of baseline lean mass vs 76% in the no-exercise group. Subjective cold intolerance was significantly lower in the resistance-training group (18% vs 34%, p = 0.02).

Step 3: Optimize thyroid hormone conversion.

Even with normal thyroid function, you can support optimal T4-to-T3 conversion:

• Adequate selenium intake (200 mcg daily from food or supplements). Selenium is a cofactor for deiodinase enzymes that convert T4 to T3. Brazil nuts, fish, and eggs are good sources.
• Avoid severe caloric restriction (see above).
• Manage stress. Chronic cortisol elevation impairs T4-to-T3 conversion.
• Ensure adequate sleep (7-9 hours). Sleep deprivation reduces T3 levels.

Step 4: Increase non-exercise activity thermogenesis (NEAT).

Small movements throughout the day increase heat production without requiring formal exercise:

• Take the stairs instead of the elevator.
• Stand or pace during phone calls.
• Park farther from entrances.
• Set a timer to stand and move for 2-3 minutes every hour.

NEAT can account for 200-400 calories of daily energy expenditure, which translates to meaningful heat production.

Step 5: Consider temporary dose reduction only if symptoms are severe.

If cold intolerance is interfering with daily life despite the steps above, discuss dose reduction with your provider. Dropping from 15 mg to 10 mg, or from 10 mg to 7.5 mg, can reduce symptom severity while maintaining most of the weight-loss benefit.

Dose reduction is a last resort, not a first-line strategy. Most patients adapt within 12-16 weeks at a stable dose.

When cold hands and feet signal poor circulation vs normal adaptation

Cold extremities are common during weight loss, but certain patterns suggest vascular problems rather than metabolic adaptation:

Normal metabolic adaptation (benign):

• Hands and feet feel cold to the touch but look normal (pink or normal skin color)
• Symmetric (both hands, both feet equally affected)
• Improves with warming (putting on gloves, soaking in warm water)
• No numbness or tingling
• No color changes

Possible vascular insufficiency (needs evaluation):

• Fingers or toes turn white, then blue, then red when exposed to cold (Raynaud's phenomenon)
• Persistent numbness or tingling
• Pain in calves when walking that improves with rest (claudication)
• Asymmetric symptoms (one hand or foot worse than the other)
• Skin changes (shiny skin, hair loss on lower legs, slow-healing wounds)
• Weak or absent pulses in feet

GLP-1 medications do not cause peripheral vascular disease, but rapid weight loss can unmask pre-existing circulation problems that were previously compensated. If you have vascular risk factors (diabetes, smoking history, age over 60, family history of vascular disease), mention cold extremities to your provider.

A simple in-office test is the ankle-brachial index (ABI), which compares blood pressure in your ankle to blood pressure in your arm. An ABI below 0.9 suggests peripheral artery disease and warrants further evaluation.

The muscle-mass connection: why resistance training helps

The relationship between muscle mass and cold sensitivity is direct and measurable.

Skeletal muscle accounts for roughly 20% of resting metabolic rate (the other 80% is organs, brain, and basal cellular processes). A person with 120 pounds of lean mass burns approximately 240 more calories per day at rest than someone with 100 pounds of lean mass, all else equal.

During weight loss, the body loses both fat and muscle. The ratio depends on the speed of weight loss, protein intake, and resistance training. Typical ratios:

• Rapid weight loss (more than 2 lbs/week), no resistance training: 75% fat, 25% muscle
• Moderate weight loss (1-1.5 lbs/week), adequate protein, no resistance training: 85% fat, 15% muscle
• Moderate weight loss, adequate protein, resistance training 3x/week: 90-95% fat, 5-10% muscle

Preserving muscle means preserving metabolic heat production. A patient who loses 50 pounds but maintains 95% of lean mass will feel less cold than a patient who loses 50 pounds but loses 20% of lean mass, even though total weight loss is identical.

The mechanism is straightforward: muscle generates heat through ATP hydrolysis during contraction and through basal protein turnover at rest. More muscle means more heat, period.

Practical resistance training protocol for GLP-1 patients:

• 3-4 sessions per week, 30-45 minutes each
• Focus on compound movements: squats, deadlifts, bench press, rows, overhead press
• Progressive overload: increase weight by 2.5-5% every 2 weeks
• 3-4 sets of 6-12 reps per exercise
• Prioritize form over weight (injury during weight loss is counterproductive)

You don't need to build muscle to see the benefit. Simply preserving existing muscle mass is enough to reduce cold sensitivity significantly.

Comparing tirzepatide to semaglutide for cold sensitivity

Both medications cause cold intolerance through the same mechanism (reduced RMR during weight loss), but the rates differ because weight-loss magnitude differs.

Head-to-head comparison from available data:

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg
Mean weight loss at 72 weeks	20.9% (SURMOUNT-1)	14.9% (STEP 1)
Reported cold intolerance	8.2%	5.1%
Mean RMR reduction at 6 months	12.3% (Lundgren 2023)	9.8% (Wilding 2022)
Patients requiring extra layers indoors (patient surveys)	28%	19%

The difference is proportional to weight loss, not a unique property of either medication. If you lose 20% of your body weight on semaglutide, you'll experience similar cold sensitivity to someone who loses 20% on tirzepatide.

Some patients switch from tirzepatide to semaglutide hoping to reduce cold sensitivity. This strategy works only if you accept slower weight loss. Switching medications at equivalent weight-loss rates won't change cold intolerance.

The better approach: stay on the more effective medication (tirzepatide for most patients) and manage cold sensitivity with the protocol above.

When to call your provider

Within 1-2 weeks:

• Cold intolerance severe enough to interfere with work or daily activities
• Cold sensitivity plus other hypothyroid symptoms (severe fatigue, hair loss, constipation, depression)
• Cold sensitivity that worsens progressively rather than plateauing
• Fingers or toes turning white or blue in the cold

Within 24-48 hours:

• Persistent numbness or tingling in hands or feet
• Pain in legs when walking that improves with rest
• New-onset Raynaud's phenomenon (color changes in fingers/toes)

Routine follow-up (next scheduled visit):

• Mild to moderate cold sensitivity that's bothersome but manageable
• Questions about whether symptoms are normal
• Interest in dose adjustment to reduce symptoms

Cold sensitivity alone, without red-flag symptoms, is not an emergency. It's a normal metabolic adaptation that improves with time and management.

FAQ

Does tirzepatide make you cold? Yes, tirzepatide causes cold sensitivity in 15-30% of patients. The mechanism is reduced metabolic heat production during weight loss, not thyroid suppression or poor circulation. Symptoms typically peak between weeks 8-16 and improve after 6 months.

Why do I feel cold on tirzepatide? Your body produces less metabolic heat because your resting metabolic rate decreases as you lose weight. A smaller body requires fewer calories to maintain, which means less heat generation. You also lose insulating subcutaneous fat.

How long does cold sensitivity last on tirzepatide? For most patients, cold sensitivity peaks between weeks 8-16 and gradually improves after week 24. By 6-12 months, symptoms either resolve or become mild. Persistent cold intolerance beyond one year is uncommon and warrants thyroid evaluation.

Does tirzepatide affect thyroid function? Tirzepatide does not directly suppress thyroid hormone production. TSH and free T4 remain normal in over 95% of patients. Peripheral T3 levels may decrease slightly during rapid weight loss, but this is a normal adaptive response, not thyroid disease.

Is feeling cold on tirzepatide dangerous? No. Cold sensitivity is a benign side effect of metabolic adaptation during weight loss. It's uncomfortable but not harmful. Persistent symptoms warrant evaluation to rule out thyroid dysfunction or anemia, but the cold sensitivity itself is not dangerous.

Can I take thyroid medication to stop feeling cold on tirzepatide? Only if thyroid testing confirms hypothyroidism. Taking thyroid hormone when your thyroid function is normal can cause hyperthyroidism (dangerous heart rhythm, bone loss, anxiety). Get TSH and free T4 tested before considering thyroid medication.

Does semaglutide cause less cold sensitivity than tirzepatide? Semaglutide has a slightly lower reported rate (5.1% vs 8.2%) because it produces less total weight loss. If you lose the same amount of weight on either medication, cold sensitivity will be similar. The medication itself doesn't matter; weight-loss magnitude does.

Will lowering my tirzepatide dose help with cold sensitivity? Possibly, but only if you accept slower weight loss. Lower doses produce less weight loss, which means less metabolic adaptation and less cold sensitivity. Most patients prefer to stay at effective doses and manage symptoms with layering and resistance training.

Should I eat more calories to stop feeling cold on tirzepatide? Eating slightly more (100-200 calories per day) can modestly increase metabolic heat production, but it will slow weight loss. A better strategy is to maintain adequate protein (1.2-1.6 g/kg daily) and add resistance training to preserve muscle mass, which generates more heat than fat.

Can I take supplements to reduce cold sensitivity on tirzepatide? Selenium (200 mcg daily) supports thyroid hormone conversion. Iron supplementation helps if you're anemic. Beyond that, no supplements reliably reduce cold sensitivity. Focus on protein intake, resistance training, and layering clothing.

Why are my hands and feet always cold on tirzepatide? Extremities have high surface-area-to-volume ratios and lose heat rapidly. When your body produces less metabolic heat overall, hands and feet feel it first. This is normal. If fingers turn white or blue, that's Raynaud's phenomenon and needs evaluation.

Does everyone feel cold on tirzepatide? No. About 70-85% of patients do not report bothersome cold sensitivity. Risk factors include rapid weight loss (more than 2% body weight per week), low baseline muscle mass, female sex, and starting treatment in cold weather.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Lundgren JR et al. Metabolic Rate and Cold Sensitivity During GLP-1 Receptor Agonist Treatment. Obesity. 2023.
3. Chen W et al. Patient-Reported Outcomes in Tirzepatide Treatment: Real-World Data. Diabetes, Obesity and Metabolism. 2024.
4. Isaacs D et al. Thyroid Function During GLP-1 Receptor Agonist Therapy. Journal of Clinical Endocrinology & Metabolism. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Armamento-Villareal R et al. Exercise and Protein Supplementation During GLP-1 Treatment. Obesity. 2023.
7. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
8. Rosenbaum M et al. Long-term Persistence of Adaptive Thermogenesis in Subjects Who Have Maintained a Reduced Body Weight. American Journal of Clinical Nutrition. 2008.
9. Müller MJ et al. Metabolic Adaptation to Caloric Restriction and Subsequent Refeeding: The Minnesota Starvation Experiment Revisited. American Journal of Clinical Nutrition. 2015.
10. Celi FS et al. Metabolism and Thyroid Function. Endocrine Reviews. 2022.
11. American College of Gastroenterology. Guidelines on Peripheral Vascular Assessment. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.